471 patents
Page 23 of 24
Utility
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
22 Jan 20
The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5).
Jaume PONS, Jeffrey Raymond CHABOT, Javier Fernando CHAPARRO RIGGERS, Bruce Charles GOMES, Hong LIANG, KapiI MAYAWALA, Jerome Thomas METTETAL, II, Arvind RAJPAL, David Louis SHELTON
Filed: 7 Mar 19
Utility
Aqueous ANTI-PD-L1 Antibody Formulation
15 Jan 20
The present invention relates to a novel anti-PD-L1 antibody formulation.
Gianluca Rinaldi, Silvia Fratarcangeli, Michael James Shopik, Alessandra Del Rio
Filed: 5 Mar 18
Utility
Antibodies Specific for GUCY2C and Uses Thereof
8 Jan 20
The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer.
Chew Shun Chang, Gurkan Guntas, Madan Katragadda, Divya Mathur, Adam Reid Root, Lidia Mosyak, Edward Roland LaVallie
Filed: 20 May 19
Utility
Sulfonyl Amide Derivatives for the Treatment of Abnormal Cell Growth
1 Jan 20
Michael Joseph Luzzio, Kevin Daniel Freeman-Cook, Samit Kumar Bhattacharya, Matthew Merrill Hayward, Catherine Angela Hulford, Christopher Lowell Autry, Xumiao Zhao, Jun Xiao, Kendra Louise Nelson
Filed: 10 Sep 19
Utility
Novel 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) Carbaldehyde Derivatives
1 Jan 20
Hui LI, Seiji NUKUI, Stephanie Anne SCALES, Min TENG, Chunfeng YIN
Filed: 16 Apr 19
Utility
Multi-site Specific Integration Cells for Difficult to Express Proteins
1 Jan 20
The present disclosure relates to a site-specific integration (SSI) mammalian cell that comprises at least two distinct recombination target sites (RTS) wherein two RTS are chromosomally-integrated within the NL1 locus or the NL2 locus.
Marc FEARY, Robert J. YOUNG, Mark MOFFAT, Gerald Fries CASPERSON, Heather Laurence JONES, Lin ZHANG
Filed: 16 Feb 18
Utility
Salts and Polymorphs of 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE
1 Jan 20
The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation.
Patricia Ann BASFORD, Anthony Michael CAMPETA, Adam GILLMORE, Matthew Cameron JONES, Eleftherios KOUGOULOS, Suman LUTHRA, Robert WALTON
Filed: 27 Feb 19
Utility
Methyl- and Trifluromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
25 Dec 19
The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand Jal Unwalla
Filed: 5 Sep 19
Utility
Antibodies Specific for CD3 and Uses Thereof
18 Dec 19
The present invention provides novel antibodies that specifically bind to CD3 and uses thereof.
James Reasoner Apgar, Fang Jin, Madan Katragadda, Divya Mathur, Lioudmila Gennadievna Tchistiakova
Filed: 20 May 19
Utility
Large Scale Production Process for Capped and Un-capped Antibody Cysteines and Their Use In Therapeutic Protein Conjugation
18 Dec 19
Optimizing production of selectively capped, and uncapped, cysteines on antibodies by manipulation of cell growth conditions including the deliberate depletion of cysteine and/or cystine in the cell culture process by way of media components, batch duration, or cell density to achieve efficient production of proteins including antibody-drug-conjugates (ADCs); conjugating a TNB-capped cysteine-containing protein by reacting it with a reducing agent capable of detaching the TNB-capping moieties from the protein without significantly reducing antibody inter-chain sulfur bonds, and conjugating reduced sulfur bonds on the protein to a payload through a reactive linking moiety.
Kaushik DUTTA, Jose Manuel GOMES, Frank W. KOTCH, Vimalkumar B. PATEL, Amarnauth Shastrie PRASHAD, Renee L. PROCOPIO-MELINO, Xiaotian ZHONG
Filed: 31 Jan 18
Utility
1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL Carbamate Derivatives and 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL Carbamate Derivatives As Magl Inhibitors
18 Dec 19
CHRISTOPHER RYAN BUTLER, LAURA ANN MCALLISTER, ELIZABETH MARY BECK, MICHAEL AARON BRODNEY, ADAM MATTHEW GILBERT, CHRISTOPHER JOHN HELAL, DOUGLAS SCOTT JOHNSON, JUSTIN IAN MONTGOMERY, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, PATRICK ROBERT VERHOEST, DAMIEN WEBB
Filed: 20 Aug 19
Utility
Crystalline Forms of 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA Maleate
18 Dec 19
This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
Eric Christian Hansen, Christopher Scott Seadeek
Filed: 24 Jul 19
Utility
GLP-1 Receptor Agonists and Uses Thereof
18 Dec 19
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Filed: 9 Jun 19
Utility
GLP-1 Receptor Agonists and Uses Thereof
18 Dec 19
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Filed: 7 Aug 19
Utility
GLP-1 Receptor Agonists and Uses Thereof
18 Dec 19
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Filed: 7 Aug 19
Utility
Purification of Antibody Drug Conjugates Using a Sodium Phosphate Gradient
4 Dec 19
Methods of removing high molecular weight species, in particular aggregates, from antibody drug conjugate preparations, by contacting preparations of the antibody drug conjugate reaction mixture with a hydroxyapatite resin and selectively eluting the ADC from the resin using a gradient comprising sodium phosphate.
Durgesh V. Nadkarni, Jeffry R. Borgmeyer, He Meng, Qingping Jiang
Filed: 6 Dec 16
Utility
Heteroaromatic Compounds and Their Use As Dopamine D1 Ligands
4 Dec 19
Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
Filed: 12 Aug 19
Utility
Crystalline Form of Lorlatinib Free Base
4 Dec 19
This invention relates to acrystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7).
Klimentina Dimitrova Pencheva, Melissa J. Birch, Mark McAllister, Martin Rowland, Ian Leonard Smales
Filed: 7 Aug 19
Utility
Immunogenic Compositions for Use in Pneumococcal Vaccines
13 Nov 19
An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates.
David Cooper, Kathrin Ute Jansen, Michael William Pride
Filed: 4 Jan 18
Utility
Calicheamicin Deratives and Antibody Drug Conjugates Thereof
13 Nov 19
The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.
Omar Khaled Ahmad, Stephen Paul Brown, Kenneth John Dirico, Russell Dushin, Gary Frederick Filzen, Sujiet Puthenveetil, Pavel Strop, Chakrapani Subramanyam, Lawrence N. Tumey
Filed: 9 Jan 18